Unicycive Therapeutics Inc. Shares Corporate Presentation Highlighting Progress in Kidney Disease Treatments and OLC Launch Readiness
Reuters
Oct 02
Unicycive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Shares Corporate Presentation Highlighting Progress in Kidney Disease Treatments and OLC Launch Readiness
Unicycive Therapeutics Inc. $(UNCY)$ has released a new corporate presentation outlining its progress in developing novel treatments for kidney disease. The company's lead asset, OLC, is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, targeting a U.S. market opportunity exceeding $1 billion. Unicycive is currently working towards the resubmission of the OLC New Drug Application (NDA) following a Complete Response Letter from the FDA, which cited issues related to a third-party manufacturing vendor but no concerns with the drug's safety or efficacy. The company has identified a second manufacturing vendor that has already produced OLC drug product and could support the resolution of these issues. Unicycive reports that its team is prepared for commercial launch pending future approval, with ongoing efforts focused on market awareness, reimbursement, and logistics. Additionally, the company is advancing its second asset, UNI-494, for the treatment of acute kidney injury and chronic kidney disease. Unicycive states that it has a cash runway expected to last into the second half of 2026. You can access the full presentation through the link below: [Full Presentation](https://docs.publicnow.com/49E60BEA08DB1ECEDFEDC6E09640A308F4790A86)
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.